161 related articles for article (PubMed ID: 23925696)
41. A survivor of breast cancer with immunity to MUC-1 mucin, and lactational mastitis.
Jerome KR; Kirk AD; Pecher G; Ferguson WW; Finn OJ
Cancer Immunol Immunother; 1997 Jan; 43(6):355-60. PubMed ID: 9067407
[TBL] [Abstract][Full Text] [Related]
42. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene.
Yin BW; Dnistrian A; Lloyd KO
Int J Cancer; 2002 Apr; 98(5):737-40. PubMed ID: 11920644
[TBL] [Abstract][Full Text] [Related]
43. Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16.
Duraisamy S; Ramasamy S; Kharbanda S; Kufe D
Gene; 2006 May; 373():28-34. PubMed ID: 16500040
[TBL] [Abstract][Full Text] [Related]
44. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
[TBL] [Abstract][Full Text] [Related]
45. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
46. Clinical significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer.
Bian J; Li B; Kou XJ; Liu TZ; Ming L
Asian Pac J Cancer Prev; 2013; 14(11):6241-3. PubMed ID: 24377511
[TBL] [Abstract][Full Text] [Related]
47. Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.
Dobrzanski MJ; Rewers-Felkins KA; Quinlin IS; Samad KA; Phillips CA; Robinson W; Dobrzanski DJ; Wright SE
Clin Immunol; 2009 Dec; 133(3):333-52. PubMed ID: 19762283
[TBL] [Abstract][Full Text] [Related]
48. Lactation mastitis: occurrence and medical management among 946 breastfeeding women in the United States.
Foxman B; D'Arcy H; Gillespie B; Bobo JK; Schwartz K
Am J Epidemiol; 2002 Jan; 155(2):103-14. PubMed ID: 11790672
[TBL] [Abstract][Full Text] [Related]
49. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models.
Chen Y; Clark S; Wong T; Chen Y; Chen Y; Dennis MS; Luis E; Zhong F; Bheddah S; Koeppen H; Gogineni A; Ross S; Polakis P; Mallet W
Cancer Res; 2007 May; 67(10):4924-32. PubMed ID: 17510422
[TBL] [Abstract][Full Text] [Related]
50. Breastfeeding, menopause, and epithelial ovarian cancer.
Siskind V; Green A; Bain C; Purdie D
Epidemiology; 1997 Mar; 8(2):188-91. PubMed ID: 9229212
[TBL] [Abstract][Full Text] [Related]
51. Mucins MUC16 and MUC1 are major carriers of SLe(a) and SLe(x) in borderline and malignant serous ovarian tumors.
Ricardo S; Marcos-Silva L; Valente C; Coelho R; Gomes R; David L
Virchows Arch; 2016 Jun; 468(6):715-22. PubMed ID: 27003157
[TBL] [Abstract][Full Text] [Related]
52. Generation and characterization of a monoclonal antibody to the cytoplasmic tail of MUC16.
Gipson IK; Mandel U; Menon B; Michaud S; Tisdale A; Campos D; Clausen H
Glycobiology; 2017 Oct; 27(10):920-926. PubMed ID: 28673046
[TBL] [Abstract][Full Text] [Related]
53. Carcinoma-associated MUC1 detected by immunoradiometric assays.
Norum LF; Varaas T; Kierulf B; Nustad K
Tumour Biol; 1998; 19 Suppl 1():134-46. PubMed ID: 9422099
[TBL] [Abstract][Full Text] [Related]
54. Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab.
Jeschke U; Wiest I; Schumacher AL; Kupka M; Rack B; Stahn R; Karsten U; Mayr D; Friese K; Dian D
Anticancer Res; 2012 May; 32(5):2185-9. PubMed ID: 22593508
[TBL] [Abstract][Full Text] [Related]
55. Humanized anti-Sialyl-Tn antibodies for the treatment of ovarian carcinoma.
Eavarone DA; Al-Alem L; Lugovskoy A; Prendergast JM; Nazer RI; Stein JN; Dransfield DT; Behrens J; Rueda BR
PLoS One; 2018; 13(7):e0201314. PubMed ID: 30052649
[TBL] [Abstract][Full Text] [Related]
56. Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.
Furrer D; Grégoire J; Turcotte S; Plante M; Bachvarov D; Trudel D; Têtu B; Douville P; Bairati I
PLoS One; 2019; 14(6):e0218621. PubMed ID: 31220149
[TBL] [Abstract][Full Text] [Related]
57. [Tumor Marker CA125: biochemical and molecular properties].
Bouanène H; Miled A
Bull Cancer; 2009 May; 96(5):597-601. PubMed ID: 19435686
[TBL] [Abstract][Full Text] [Related]
58. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.
Wang L; Chen H; Pourgholami MH; Beretov J; Hao J; Chao H; Perkins AC; Kearsley JH; Li Y
PLoS One; 2011; 6(9):e24405. PubMed ID: 21931707
[TBL] [Abstract][Full Text] [Related]
59. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.
Comamala M; Pinard M; Thériault C; Matte I; Albert A; Boivin M; Beaudin J; Piché A; Rancourt C
Br J Cancer; 2011 Mar; 104(6):989-99. PubMed ID: 21326240
[TBL] [Abstract][Full Text] [Related]
60. Improved soluble expression of a single-chain antibody fragment in E. coli for targeting CA125 in epithelial ovarian cancer.
Sharma SK; Suresh MR; Wuest FR
Protein Expr Purif; 2014 Oct; 102():27-37. PubMed ID: 25079010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
